Immunovant, Inc. vs Merck & Company, Inc. — Stock Comparison
Immunovant, Inc. (IMVT) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. clearly outscores Immunovant, Inc. on Q·Score (7 vs 5.4 out of 10), led by Quality (7.7 vs 1.6) and Growth (6.2 vs 5.1). Immunovant, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for IMVT (+31.8%) than for MRK (+12.4%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.0× debt-to-equity).
⚠ low return on equity (-65%).
High-quality business with 19% return on equity and 14% profit margins.
Analyst Consensus
Fundamentals
Frequently Asked Questions
IMVT vs MRK: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 7/10 versus Immunovant, Inc. (IMVT) at 5.4/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: IMVT or MRK?
Merck & Company, Inc. (MRK) scores higher on Growth (6.2/10 vs 5.1/10). Immunovant, Inc. reports revenue growth while Merck & Company, Inc. reports (4.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is IMVT or MRK more attractively valued?
Merck & Company, Inc. (MRK) scores higher on Valuation (6.7/10 vs 5.7/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about IMVT vs MRK?
There are 17 analysts covering IMVT with a consensus price target of $45.76, and 27 analysts covering MRK with a consensus target of $129.74. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: IMVT or MRK?
Merck & Company, Inc. (MRK) scores higher on Quality (7.7/10 vs 1.6/10). Net profit margin: IMVT at 0.0%, MRK at 13.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: IMVT or MRK?
Immunovant, Inc. (IMVT) scores higher on Financial Health (8.7/10 vs 7/10). Market beta: IMVT at 0.79, MRK at 0.22. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of IMVT and MRK?
Immunovant, Inc. (IMVT) has a market capitalisation of $7.1B, while Merck & Company, Inc. (MRK) has a market cap of $285.1B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do IMVT or MRK pay dividends?
IMVT does not currently pay a dividend, while MRK pays a dividend yield of 2.95%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →